{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:24:30Z","timestamp":1787156670134,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtha.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:40:26Z","timestamp":1782492026000},"page":"3308-3324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Manipulating CD38 ectoenzymatic activity revitalizes regulatory T cells via deacetylase Sirt-1 in immune thrombocytopenia"],"prefix":"10.1016","volume":"24","author":[{"given":"Mingfang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-1882","authenticated-orcid":false,"given":"Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.06.019_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2008.02.005","article-title":"CD38 at the junction between prognostic marker and therapeutic target","volume":"14","author":"Deaglio","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jtha.2026.06.019_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/ITT.S259122","article-title":"CD38-directed therapies for management of multiple myeloma","volume":"10","author":"Hashmi","year":"2021","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jtha.2026.06.019_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: an important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtha.2026.06.019_bib5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3390\/cells9071716","article-title":"CD38: T cell immuno-metabolic modulator","volume":"9","author":"Kar","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2026.06.019_bib7","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.bbapap.2009.10.022","article-title":"SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions","volume":"1804","author":"Zhang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jtha.2026.06.019_bib8","article-title":"Regulation of SIRT1 and its roles in inflammation","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.14348\/molcells.2016.2318","article-title":"Sirt1 and the mitochondria","volume":"39","author":"Tang","year":"2016","journal-title":"Mol Cells"},{"key":"10.1016\/j.jtha.2026.06.019_bib10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.kint.2016.01.020","article-title":"Juicing Tregs in situ to improve kidney allograft outcomes","volume":"89","author":"Fairchild","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtha.2026.06.019_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/MCB.01206-10","article-title":"Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival","volume":"31","author":"Beier","year":"2011","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtha.2026.06.019_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2018-07-863233","article-title":"Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice","volume":"133","author":"Daenthanasanmak","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1042\/CS20171410","article-title":"Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis","volume":"132","author":"Olivares","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jtha.2026.06.019_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/1871530321666210309112234","article-title":"Dysregulation of SIRT-1 signaling in multiple sclerosis and neuroimmune disorders: a systematic review of SIRTUIN activators as potential immunomodulators and their influences on other dysfunctions","volume":"21","author":"Sharma","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jtha.2026.06.019_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2020.07.004","article-title":"Hsa_circ_0088036 promotes the proliferation and migration of fibroblast-like synoviocytes by sponging miR-140-3p and upregulating SIRT 1 expression in rheumatoid arthritis","volume":"125","author":"Zhong","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib16","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib17","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood.2025029006","article-title":"Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia","volume":"145","author":"Gao","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/biom12091261","article-title":"Molecular determinants underlying the anti-cancer efficacy of CD38 monoclonal antibodies in hematological malignancies","volume":"12","author":"Mustafa","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jtha.2026.06.019_bib19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/BOR.0000000000000737","article-title":"The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis","volume":"32","author":"Peclat","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jtha.2026.06.019_bib20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jtha.2023.03.010","article-title":"Anti-CD38 antibody for refractory acquired hemophilia A","volume":"21","author":"Liu","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.019_bib21","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.06.019_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2025017279","article-title":"Safety and efficacy of daratumumab in immune thrombocytopenia","volume":"10","author":"Tsykunova","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.06.019_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bjh.19553","article-title":"The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China","volume":"205","author":"Hu","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtha.2026.06.019_bib25","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/bjh.19660","article-title":"Long-term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: a case series","volume":"205","author":"Str\u00fc\u00dfmann","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib26","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMc2501527","article-title":"Daratumumab in relapsed or refractory pediatric immune thrombocytopenia","volume":"392","author":"Sun","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.019_bib27","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/ajh.27448","article-title":"2025 update on clinical trials in immune thrombocytopenia","volume":"99","author":"Al-Samkari","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084314","article-title":"Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial","volume":"391","author":"Chen","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.06.019_bib29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.019_bib30","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.06.019_bib31","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/bloodadvances.2020003860","article-title":"Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia","volume":"5","author":"Yu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.06.019_bib32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.019_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0609.2005.00622.x","article-title":"Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura","volume":"76","author":"Zhang","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.19079","article-title":"The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia","volume":"203","author":"Yazdanbakhsh","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib35","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2015-10-674531","article-title":"High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia","volume":"127","author":"Hou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3324\/haematol.2022.281557","article-title":"Enhancing regulatory T-cell function via inhibition of high mobility group box 1 protein signaling in immune thrombocytopenia","volume":"108","author":"Wang","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.06.019_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2020008477","article-title":"Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia","volume":"138","author":"Han","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib38","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2009-09-244772","article-title":"A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy","volume":"115","author":"Chow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176851","article-title":"Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation","volume":"134","author":"Wang","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2026.06.019_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ng1952","article-title":"Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres","volume":"39","author":"Benetti","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2026.06.019_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112790","article-title":"Suppression of latent transforming growth factor-\u03b2 (TGF-\u03b2)-binding protein 1 (LTBP1) inhibits natural killer\/T cell lymphoma progression by inactivating the TGF-\u03b2\/Smad and p38MAPK pathways","volume":"407","author":"Lin","year":"2021","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jtha.2026.06.019_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1083\/jcb.200809167","article-title":"A c-Myc-SIRT1 feedback loop regulates cell growth and transformation","volume":"185","author":"Yuan","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jtha.2026.06.019_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/mi.2014.10","article-title":"Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells","volume":"7","author":"Akimova","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002873","article-title":"Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms","volume":"5","author":"Beier","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.jtha.2026.06.019_bib45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2017.08.010","article-title":"An NF-\u03baB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function","volume":"47","author":"Oh","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jtha.2026.06.019_bib46","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bbapap.2010.05.002","article-title":"SIRT1 and p53, effect on cancer, senescence and beyond","volume":"1804","author":"Yi","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jtha.2026.06.019_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtha.2026.06.019_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138161209787185788","article-title":"CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions","volume":"15","author":"Chini","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jtha.2026.06.019_bib49","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/bjh.19820","article-title":"Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia","volume":"205","author":"Li","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/cancers13010076","article-title":"Daratumumab and nanobody-based heavy chain antibodies inhibit the ADPR cyclase but not the NAD(+) hydrolase activity of CD38-expressing multiple myeloma cells","volume":"13","author":"Baum","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2026.06.019_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.12480","article-title":"Cellular immune dysfunction in immune thrombocytopenia (ITP)","volume":"163","author":"McKenzie","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.019_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.06.019_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2026.06.019_bib54","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtha.2026.06.019_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt2117","article-title":"CD38-mediated metabolic reprogramming promotes the stability and suppressive function of regulatory T cells in tumor","volume":"11","author":"Sarkar","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtha.2026.06.019_bib56","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","article-title":"Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients","volume":"105","author":"Kitadate","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.06.019_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2026.06.019_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtha.2026.06.019_bib60","article-title":"Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.06.019_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.019_bib62","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.06.019_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70493","article-title":"Anti-CD38 therapy in immune thrombocytopenia (ITP)","author":"Ghanima","year":"2026","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:28:38Z","timestamp":1787153318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626004046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1538783626004046"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.06.019","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manipulating CD38 ectoenzymatic activity revitalizes regulatory T cells via deacetylase Sirt-1 in immune thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}